Literature DB >> 10174318

Current issues in German healthcare.

J M Graf von der Schulenburg1, A Uber.   

Abstract

Germany has developed a model of social health insurance for financing healthcare. The basic characteristics of this model are compulsory membership, income-dependent contributions paid by employers and employees, a comprehensive package of healthcare entitlements, stringent government regulation and implementation by not-for-profit health insurers--the sickness funds--which operate under public law. Since the mid-1970s, when health care cost containment gradually evolved as a new issue in German healthcare policy-making, a long series of reform programmes have been initiated. Two recent development can be noted: the introduction of market competition in health insurance and the introduction of fixed budgets. Market competition in health insurance is now an explicit policy tool in Germany. This article analyses the German healthcare system, the history of healthcare reforms and the current healthcare acts. Special emphasis is given to the German drug market and its regulation. The paper describes the present cost-containment policy for pharmaceutical products, especially the global budget concept which was introduced for medicines and patients' copayments.

Entities:  

Mesh:

Year:  1997        PMID: 10174318     DOI: 10.2165/00019053-199712050-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  3 in total

Review 1.  Consequences of implementing a drug budget for office-based physicians in Germany.

Authors:  O Schöffski
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

2.  Germany: solidarity at a price.

Authors:  J M Graf van der Schulenburg
Journal:  J Health Polit Policy Law       Date:  1992       Impact factor: 2.265

3.  The socioeconomic profile of patients treated by phlebotropic drugs in Germany.

Authors:  A Uber
Journal:  Angiology       Date:  1997-07       Impact factor: 3.619

  3 in total
  3 in total

Review 1.  Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.

Authors:  Lisa L Ioannides-Demos; Joseph E Ibrahim; John J McNeil
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  Cost-effectiveness of ceftriaxone 1 g vs second-generation cephalosporins in the treatment of pneumonia in general medical wards in Germany.

Authors:  E S Dietrich; U Joseph; F Vogel; S Howaldt; K H Kullmann; U Frank; F D Daschner
Journal:  Infection       Date:  1999 Mar-Apr       Impact factor: 3.553

3.  European healthcare policies for controlling drug expenditure.

Authors:  Silvia M Ess; Sebastian Schneeweiss; Thomas D Szucs
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.